论文部分内容阅读
对１０１例原发性肝癌（ＰＨＣ）同步检测几项标记，其阳性率为ＡＦＰ７６．２％，ＧＧＴⅡ８５．１％，ＡＬＰⅠ２４．８％，ＡＡＴ７５．１％。与肝硬化、慢性肝炎、肝良性占位性病变、肝外肿瘤、正常人等组比较，差异有显著性。假阳性率以肝硬化用组高，分别为ＡＦＰ１５．０％，ＧＧＴⅡ１０．０％，ＡＬＰⅠ３．３％，ＡＡＴ２６．７％。在ＡＦＰ＜５０ｎｇ／ｍｌ２４例中，ＧＧＴⅡ阳性率为７０．８％，ＡＬＰⅠ为１６．７％，ＡＡＴ为６６．７％。本文结果显示、ＧＧＴⅡ诊断ＰＨＣ敏感性、特异性均佳，优于ＡＦＰ、ＡＬＰⅠＩ及ＡＡＴ。ＧＧＴⅡ与ＡＦＰ互补诊断可提高阳性率。
A number of markers were simultaneously detected in 101 cases of primary liver cancer (PHC). The positive rates were 76.2% for AFP, 85.1% for GGTII, 24.8% for ALPI, and 75.1% for AAT. Compared with liver cirrhosis, chronic hepatitis, liver benign lesions, extrahepatic tumors, normal people and other groups, the difference was significant. The false positive rate was higher in the cirrhosis group, which was AFP 15.0%, GGT II 10.0%, ALPI 3.3%, and AAT 26.7%. In 24 cases with AFP <50 ng/ml, the positive rate of GGTII was 70.8%, the ALPI was 16.7%, and the AAT was 66.7%. The results of this study showed that the sensitivity and specificity of GGTII in diagnosing PHC were better than AFP, ALPII and AAT. The complementary diagnosis of GGTII and AFP can increase the positive rate.